Literature DB >> 16505489

Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.

Michael Jeltsch1, Terhi Karpanen, Tomas Strandin, Kukka Aho, Hilkka Lankinen, Kari Alitalo.   

Abstract

Vascular endothelial growth factors (VEGFs) and their receptors play key roles in angiogenesis and lymphangiogenesis. VEGF activates VEGF receptor-1 (VEGFR-1) and VEGFR-2, whereas VEGF-C activates VEGFR-2 and VEGFR-3. We have created a library of VEGF/VEGF-C mosaic molecules that contains factors with novel receptor binding profiles, notably proteins binding to all three VEGF receptors ("super-VEGFs"). The analyzed super-VEGFs show both angiogenic and lymphangiogenic effects in vivo, although weaker than the parental molecules. The composition of the VEGFR-3 binding molecules and scanning mutagenesis revealed determinants of receptor binding and specificity. VEGFR-2 and VEGFR-3 showed striking differences in their requirements for VEGF-C binding; extracellular domain 2 of VEGFR-2 was sufficient, whereas in VEGFR-3, both domains 1 and 2 were necessary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505489     DOI: 10.1074/jbc.M511593200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.

Authors:  Jianguo Li; Nidal Al-Huniti; Anja Henningsson; Weifeng Tang; Eric Masson
Journal:  Br J Clin Pharmacol       Date:  2017-03-27       Impact factor: 4.335

3.  Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.

Authors:  Nidal Al-Huniti; Klas Petersson; Weifeng Tang; Eric Masson; Jianguo Li
Journal:  Br J Clin Pharmacol       Date:  2018-01-31       Impact factor: 4.335

4.  Structural determinants of growth factor binding and specificity by VEGF receptor 2.

Authors:  Veli-Matti Leppänen; Andrea E Prota; Michael Jeltsch; Andrey Anisimov; Nisse Kalkkinen; Tomas Strandin; Hilkka Lankinen; Adrian Goldman; Kurt Ballmer-Hofer; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-09       Impact factor: 11.205

5.  Characterization of the interaction between endostatin short peptide and VEGF receptor 3.

Authors:  Kyu-Yeon Han; Dimitri T Azar; Abdellah Sabri; Hyun Lee; Sandeep Jain; Bao-Shiang Lee; Jin-Hong Chang
Journal:  Protein Pept Lett       Date:  2012-09       Impact factor: 1.890

6.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

Review 7.  The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases.

Authors:  Richard M Monaghan; Donna J Page; Pia Ostergaard; Bernard D Keavney
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

8.  Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.

Authors:  Matthias Rinderknecht; Alessandra Villa; Kurt Ballmer-Hofer; Dario Neri; Michael Detmar
Journal:  PLoS One       Date:  2010-08-02       Impact factor: 3.240

9.  Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.

Authors:  Veli-Matti Leppänen; Denis Tvorogov; Kaisa Kisko; Andrea E Prota; Michael Jeltsch; Andrey Anisimov; Sandra Markovic-Mueller; Edward Stuttfeld; Kenneth N Goldie; Kurt Ballmer-Hofer; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

Review 10.  The role of the VEGF-C/VEGFRs axis in tumor progression and therapy.

Authors:  Jui-Chieh Chen; Yi-Wen Chang; Chih-Chen Hong; Yang-Hao Yu; Jen-Liang Su
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.